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Abstract
Background: In the UK, hepatitis B virus (HBV) incidence is associated with migrants from particular high-burden
countries and population groups deemed ‘hard-to-reach’ by standard healthcare services: the homeless, people
who inject drugs and ex-prisoners. Currently, there is a national targeted HBV vaccine policy for such at-risk groups,
but there is limited recent evidence about 1) the levels of vaccine uptake, 2) the factors associated with incomplete
vaccination, and 3) reasons for incomplete vaccination.
Methods: A questionnaire capturing social and medical history, demographic factors and information about HBV
vaccination status was completed by individuals deemed hard-to-reach due to socio-structural factors that criminalise,
isolate and stigmatise who consented to participate in a randomised controlled trial of a peer intervention to promote
engagement with hepatitis C services. The questionnaire also captured the reasons for incomplete vaccination.
Descriptive, univariable and multivariable regression analyses were undertaken.
Results: Three hundred fourty six participants completed the questionnaire. 1) 52.3% (n = 181) reported full HBV
vaccination. 2) Within a multivariable model adjusting for sociodemographic variables, the presence of one or two
or more socio-structural factors that are included in the national targeted vaccination policy was associated with
protection against incomplete HBV vaccination (51.7% vaccine coverage in those with one factor, odds ratio 0.43 [95%
confidence interval 0.20–0.92]); 70.1% coverage with two or more factors, 0.19 [0.09–0.39]; overall p-value < 0.001).
Being female was also associated with lower vaccine uptake (2.37 [1.24–4.57], 0.01). Examining the socio-structural
factors individually, intravenous drug use was associated with protection against incomplete HBV vaccination. 3) The
most common reasons declared for incomplete vaccination were never being offered the vaccine or not returning for
further doses.
Conclusion: Within this study of HBV vaccination uptake among hard-to-reach population groups in London, UK, we
document 52.3% coverage of the full vaccine course. Critically, although participants recommended for immunisation
within national guidelines had an increased likelihood of receiving a complete vaccine course, we note surprisingly
low coverage in the presence of the risk factors that are national indicators for vaccination. Public health bodies should
make additional efforts to improve coverage in the hard-to-reach through improved vaccine delivery systems.
Trial registration: ISRCTN24707359, Registered 19th October 2012.
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Background
The global burden of hepatitis B virus (HBV) is substan-
tial, with 257 million people living with chronic infection
globally [1]. Chronic infections can lead to cirrhosis and
hepatocellular carcinoma and cause around 500,000–
700,000 deaths a year [2]. In the UK in 2017, the inci-
dence of infection was low at 0.80/100,000, [3] but it
was concentrated in specific population groups, includ-
ing migrants from high burden countries and individuals
deemed ‘hard-to-reach’ by healthcare services due to
socio-structural factors that criminalise, isolate and stig-
matise, such as homelessness, injecting drug use (IDU)
and imprisonment [4, 5]. In order to fulfil its commit-
ment to viral hepatitis elimination by 2030, the UK
needs to effectively address infection prevention and
treatment in these groups [6].
A HBV subunit vaccine has been available since 1982
and is 95% effective at preventing infection in people who
have completed the three dose schedule (zero, one and six
months) [7]. A rapid schedule can also be used (zero, seven
and 21 days), with a fourth dose recommended for ongoing
protection [8]. In the UK, HBV vaccination has historically
been targeted towards population groups such as people
who inject drugs (PWIDs), individuals who change sexual
partners frequently (particularly men who have sex with
men), patients with chronic liver disease (particularly with
chronic hepatitis C virus infection [HCV]), prisoners and
those at occupational risk. These target groups are laid out
in the Green Book, published by Public Health England
(PHE) [8]. Since the autumn of 2017, HBV vaccination for
all children aged one to 10 has also been incorporated into
the UK immunisation schedule [8].
Although homelessness is not a specific indicator for
HBV vaccination in the UK, this population group over-
laps with the target groups of the Green Book. Previous
research has highlighted the association between home-
lessness and tri-morbidity (the combination of physical
and mental ill-health and substance abuse), unprotected
sex, exposure to blood-borne viruses and IDU [9–14]. The
cycle of homelessness and imprisonment is also well doc-
umented [15–17]. The homeless are disproportionately
represented in the population of those experiencing the
criminal justice system and homelessness can be a major
factor in both offending and re-offending. There is often a
lack of housing and support options available to individ-
uals leaving custody. It has also been suggested that the
homeless will re-offend to keep a roof over their head.
The latest figures estimate the homeless population in
London to be over 164,000, with around 3% living in single
bed homeless hostels [18]. The majority of the
rough-sleeping population in London identify as White
British and White Other (35 and 28%, respectively) [19].
The nationalities of the 46% of non UK-born rough
sleepers is diverse. In recent years, the proportion of rough
sleepers from Central and Eastern European Countries has
declined (23% in 2017/18 compared to 37% in 2015/16).
People born in Romania and Poland make up the two lar-
gest non-UK nationalities (9 and 8% respectively) [19].
Individuals within these population groups often have
difficulties in accessing traditional healthcare systems [5,
20]. Outreach services such as ‘Find and Treat’ in London-
which seeks to detect tuberculosis in hard-to-reach groups
and support people through diagnosis and treatment-
exist to meet the health needs of vulnerable individuals by
engagement with homeless shelters, etc., but there is often
a lack of coordination between boroughs and the National
Health Service (NHS) [21].
In order to understand how effectively the national pub-
lic health vaccination policy documented in the Green
Book is being implemented among risk groups, this study
aimed to assess the levels of HBV vaccine coverage in a
hard-to-reach population in London, the epidemiological
factors associated with coverage, and the individual rea-
sons for not completing the vaccine course.
Methods
Study design and participants
The HALT: Hepatitis trial was a randomised non-blinded
controlled trial to assess the efficacy of a Peer Advocacy
intervention to promote engagement with healthcare ser-
vices in individuals chronically infected with viral hepatitis
[22]. Potential trial participants were approached through
outreach services such as drug treatment centres, home-
less hostels and day centres across London, UK between
August 2013 and June 2015. The eligibility criteria were
being hard-to-reach by normal healthcare services
(evidenced by engagement with outreach services as a cli-
ent), over the age of 16 years, and providing written in-
formed consent. Individuals were excluded if they were
already on treatment for hepatitis C virus (HCV) or HBV.
In order to fully enrol in the trial, consenting participants
had to test positive HBV or HCV infection.
This study is a cross-sectional analysis of the data col-
lected at baseline from the potential trial participant
population i.e. it does not exclude anyone by HBV or
HCV status. A questionnaire captured self-reported
demographic and clinical information, including whether
participants had been vaccinated against HBV and how
many doses they had received (Additional file 1). Partici-
pants were also asked to select a reason for not receiving
the vaccine or receiving less than three doses.
Study outcome
The outcome of interest was having an incomplete
self-declared HBV vaccination history (less than three
doses). Self-declared HBV vaccination status was classi-
fied as: no doses, one dose, two doses, three or more
doses, or unknown status. For the regression model, zero
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to two doses were combined into a single stratum (in-
complete vaccination status).
Exposures of interest
Homelessness was collated into a variable with four strata:
unknown, never homeless, ever homeless, or currently
homeless. Current homelessness outranked previous
homelessness. Drug use was categorised as current IDU,
history of IDU, non-IDU (this captured those who stated
that they had used drugs non-intravenously in the past or
currently), no drug use, and unknown. Current IDU out-
ranked history of IDU, IDU outranked non-IDU. Impris-
onment was categorised into ever imprisoned, ever
arrested but not imprisoned, neither, and unknown. Ex-
cessive alcohol consumption and smoking history was
documented as present, absent, and unknown. Informa-
tion about smoking combined into the single variable
‘smoking history’, which combined questions on the num-
ber of cigarettes a day and current or previous smoking to
yield the strata Present, Absent, and Unknown.
Given the critical nature of the Green Book in provid-
ing vaccination guidance [8], the presence of zero, one,
or two or more Green Book risk factors that should trig-
ger the offer of vaccination were recorded in a single
variable. The factors included were thus socio-structural
factors that criminalise and stigmatise i.e. drug use,
homelessness, imprisonment, being arrested, and liver
disease (all from the baseline questionnaire), as well as
HCV status derived from laboratory tests.
Analysis
Descriptive analyses were undertaken of vaccine uptake,
the number of doses taken and reasons for not accepting
a full course of vaccination.
Logistic regression models were used to identify fac-
tors associated with the outcome of complete HBV vac-
cination using Stata version 14. Initially, univariable
models were built that included the Green Book classifi-
cation of target groups (by socio-structural factors). As
our analysis looked at multiple potential factors associ-
ated with vaccination status, all exposures from the uni-
variable analyses were included in the multivariable
model, which was assessed for model stability and collin-
earity. For consistency, the univariable models were re-
stricted to the same participants as were included in the
multivariable regression. Likelihood Ratio tests (LRTs)
were used to examine a priori defined potential effect
modification between Green Book risk factors and
homelessness, Green Book risk factors and alcohol
abuse, homelessness and alcohol abuse, and ethnicity
and birthplace, as well as to assess if model fit was im-
proved by the inclusion of age as a linear or categorical
variable. Later analyses looked at the individual
associations between the factors documented in the
Green Book and vaccine uptake.
Ethics
This secondary data analysis was approved as part of the
HALT: Hepatitis trial by the National Research Ethics Ser-
vice (NRES) Committee London, Brent (ref: 13/LO/0077)
and was registered as ISRCTN24707359 [23].
Results
Participant characteristics
Three hundred sixty four individuals consented for test-
ing as part of the trial; of these 18 declared a previous
HBV diagnosis and were thus excluded, leaving 346
(95.1%). Table 1 describes the baseline characteristics of
the remaining 346 participants. The majority were male
(264/346, 76.3%) and UK-born (263/346, 76.0%), with a
median age of 43 years (range 19–69). 176/346 (50.9%)
reported current or previous IDU, 289/346 current or
previous homelessness (83.5%) and 221/346 (63.9%) im-
prisonment. 228/346 (65.9%) participants reported re-
ceiving a previous HBV test. 157 (45.4%) participants
had two or more of the risk factors listed in the Green
Book, with 246 (71.1%) reporting at least one.
Level of HBV vaccination
The level of complete self-declared HBV vaccination in
this cohort was 52.3% (Table 1). 227/346 (65.6%) partici-
pants stated that they had received at least one dose of
HBV vaccine. Of these, 181/227 (79.7%) had a complete
vaccination status (three doses), 15/227 (6.6%) reported
receiving one dose of HBV vaccine and 26/227 (11.5%)
reported receiving two doses. Participants reporting in-
complete vaccination status (less than three doses) were
more likely to be female (52%, 43/82), have never been
homeless (51%, 26/51), to declare no drug use (65%, 44/
68), and to have never been imprisoned or arrested
(62%, 28/45). Examining the individuals with an un-
known vaccination status revealed that they may be
older, with a differing history of drug use, and imprison-
ment/arrest (Additional file 2).
When contributing risk factors were summarised into a
single ‘Green Book’ variable, the percentage of participants
with an incomplete vaccine status decreased from 58.4%
(zero Green Book risk factors) to 40.5% (one) and 22.9%
(two or more). When broken down into doses, the per-
centage of participants reporting zero and one dose of
HBV vaccination was highest in those reporting zero
Green Book risk factors (42.2 and 40.0% respectively). In
comparison, with two and three or more doses, the per-
centage was highest in participants with two or more
Green Book risk factors (50.0 and 60.8% respectively).
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Table 1 Baseline characteristics of the 346 participants, by number of doses of HBV vaccine
Variables Overall Incomplete vaccination status Complete vaccination status Unknown vaccination status
# Col % # Row % # Row % # Row %
Overall 346 100 130 37.6 181 52.3 35 10.1
Gender
Female 82 23.7 43 52.4 30 36.6 9 11.0
Male 264 76.3 87 33.0 151 57.2 26 9.8
Unknown 0 0.0 0 – 0 – 0 –
Age
19–29 53 15.3 24 45.3 25 47.2 4 7.6
30–39 86 23.9 28 32.6 51 59.3 7 8.1
40–49 140 41.5 48 34.3 81 57.8 11 7.9
50–59 60 17.9 25 41.7 22 36.7 13 21.7
60–69 7 2.2 5 71.4 2 28.6 0 0.0
Unknown 0 0.0 0 – 0 – 0 –
Ethnicity
White C/E European 82 23.7 33 40.2 37 45.1 12 14.6
White Other 160 46.8 53 33.1 89 55.6 18 11.3
Black African 25 7.2 16 64.0 9 36.0 0 0.0
Black Other 45 13.0 16 35.6 27 60.0 2 4.4
Mixed/Other 32 9.2 11 34.4 18 56.3 3 9.4
Unknown 2 0.6 1 50.0 1 50.0 0 0.0
Birthplace
Not UK born 83 24.0 38 45.8 33 39.8 12 14.6
UK born 263 76.0 92 35.0 148 56.2 23 8.7
Unknown 0 0.0 0 – 0 – 0 –
Drug use
No drug use 68 19.7 44 64.7 14 20.6 10 14.7
Non-IDU (History or current) 101 29.2 43 42.6 44 43.6 14 13.9
History of IDU 98 28.3 22 22.5 67 68.4 9 9.18
Current IDU 78 22.5 20 25.6 56 71.8 2 2.6
Unknown 1 0.0 1 100.0 0 – 0 –
Homelessness
Never 51 14.7 26 51.0 21 41.2 4 7.8
History 104 30.1 29 27.9 63 60.6 12 11.5
Current 185 53.5 72 38.9 94 50.8 19 10.3
Unknown 6 1.2 3 50.0 3 50.0 0 –
Imprisonment/Arrested
Neither 45 13.0 28 62.2 12 26.7 5 11.1
Arrested but not imprisoned 78 22.5 40 51.3 22 28.2 16 20.5
Imprisoned 221 64.2 61 27.6 146 66.1 14 6.3
Unknown 2 0.6 1 50.0 1 50.0 0 –
Excess alcohol consumption
No 203 58.7 80 39.1 104 51.2 19 9.4
Yes 141 40.8 50 35.5 75 53.2 16 11.4
Unknown 2 0.6 0 – 2 100.0 0 –
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Predictors of incomplete vaccine status
In univariable and multivariable models (Table 2), 63 in-
dividuals with missing data (28 missing information on
exposures, 35 missing information on the outcome of
interest) were excluded and age was included as a linear
variable (p = 0.34).
Within the univariable models, Green Book risk fac-
tors were initially examined within a single variable.
Having two or more risk factors versus none was associ-
ated with protection against having an incomplete HBV
vaccination status (odds ratio [OR] 0.13 [95% confidence
interval {CI} 0.07–0.26). Having one risk factor was also
associated with protection, albeit to a lesser degree (0.32
[0.16–0.66]), although the CIs between the two strata
overlapped. Being female (2.78 [1.59–4.89], p < 0.001)
was associated with higher odds of having an incomplete
vaccination status. There was also an association be-
tween people who have smoked (either currently or in
the past) with having a complete HBV vaccination status
(5.73 [2.06–15.88], p < 0.001).
In a multivariable model, the association between
Green Book risk factors and incomplete vaccination sta-
tus was maintained (one factor 0.43 [0.20–0.92]); two or
more factors, 0.19 [0.09–0.39]; overall p-value < 0.001).)
Being female (2.37 (1.24–4.57), p = 0.01) also remained
associated with incomplete vaccination.
There was no statistical evidence for interactions
between Green Book risk factors and homelessness (LRT
p = 0.79), Green Book risk factors and alcohol abuse
(p = 0.24), ethnicity and birthplace (p = 0.84), or home-
lessness and alcohol abuse (p = 0.97).
Additional analyses were also undertaken examining
the impact of the Green Book risk factors (drug use, im-
prisonment/arrest, history of liver disease, HCV status)
as individual variables (Table 3). Intravenous drug use
(history 0.17 [0.06–0.49]); current, 0.23 [0.08–0.62];
overall p-value 0.004) was associated with protection
against incomplete HBV vaccination.
Reasons for incomplete vaccination
Specific reasons for not receiving any doses of HBV vac-
cine were declared by 85 participants (Table 4). The
most common reason was never being offered vaccin-
ation, with 80% (68/85) of participants stating this as a
reason for no vaccination. 41% (28/68) of participants
who reported never having been offered the vaccine had
at least one of the factors listed in the Green Book, iden-
tifying them as targets for the pre-exposure immunisa-
tion programme.
Twenty two of 42 participants who had an incomplete
vaccination status (one or two doses) gave a reason for
not completing the vaccine schedule. The most common
Table 1 Baseline characteristics of the 346 participants, by number of doses of HBV vaccine (Continued)
Variables Overall Incomplete vaccination status Complete vaccination status Unknown vaccination status
# Col % # Row % # Row % # Row %
Smoking History
Absent 28 8.1 18 64.3 5 17.9 5 17.9
Present 318 91.9 112 35.2 176 55.4 30 9.4
Unknown 0 0 0 – 0 – 0 –
Liver Disease
No 282 81.5 100 35.5 155 55.0 27 9.6
Yes 43 12.4 18 41.9 19 44.2 6 14.0
Unknown 21 6.1 12 57.1 7 33.3 2 9.5
HCV status
Negative 247 71.4 105 42.5 114 46.2 28 11.3
Positive 95 27.4 24 25.3 65 68.4 6 6.3
Unknown 4 2.7 1 25.0 2 50.0 1 25.0
Green Book risk factors*
0 77 22.3 45 58.4 17 22.1 15 19.5
1 89 25.7 36 40.5 46 51.7 7 7.9
2 or more 157 45.4 36 22.9 110 70.1 11 7.0
Unknown 23 6.6 13 56.5 8 34.8 2 8.7
Complete vaccination status was recorded as three or more doses. C/E Central and Eastern, Col column, IDU injecting drug use, HCV Hepatitis C virus
*Green Book risk factors include current or intermittent drug use (history of IDU and current IDU), being imprisoned, having liver disease and additionally being
infected with HCV on top of having liver disease
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reason was that they did not return after their initial
dose(s) (Table 4).
Discussion
In a population of hard-to-reach individuals from home-
less and outreach centres across London, the study found
that only 52% had received a full three-dose course of
HBV vaccine, with 74% of participants reporting at least
one dose. Critically, although the proportion of individuals
Table 2 Factors associated with an incomplete HBV vaccination
course (less than 3 doses) in hard-to-reach individuals
Variable Univariable
regression
Multivariable
regression
OR (95% CI) OR (95% CI)
Gender p < 0.001 p = 0.01
Male (base) (base)
Female 2.78 (1.59–4.89) 2.37 (1.24–4.57)
Age (linear) p = 0.80 p = 0.07
19–29 (base) (base)
per 10 year increase 1.03 (0.82–1.30) 1.30 (0.98–1.72)
Ethnicity p = 0.29 p = 0.90
White C/E European 1.28 (0.69–2.36) 1.16 (0.58–2.34)
White Other (base) (base)
Black African 2.57 (1.04–6.38) 1.27 (0.37–4.33)
Black Other 0.91 (0.45–1.89) 0.77 (0.34–1.76)
Mixed/Other 1.03 (0.43–2.46) 0.83 (0.32–2.18)
Birthplace p = 0.06 p = 0.65
UK born (base) (base)
Not UK born 1.7 (0.97–2.99) 1.19 (0.56–2.51)
Homelessness p = 0.02 p = 0.31
Never (base) (base)
History 0.34 (0.16–0.74) 0.68 (0.28–1.67)
Current 0.62 (0.31–1.22) 1.11 (0.49–2.50)
Excessive alcohol consumption p = 0.24 p = 0.65
No (base) (base)
Yes 0.74 (0.57–1.03) 0.88 (0.50–1.54)
Smoking history p < 0.001 p = 0.02
Absent (base) (base)
Present 0.17 (0.06–0.46) 0.29 (0.09–0.89)
Green Book risk factors* p < 0.001 p < 0.001
0 (base) (base)
1 0.32 (0.16–0.66) 0.43 (0.20–0.92)
2 or more 0.13 (0.07–0.26) 0.19 (0.09–0.39)
All models present a complete case analysis where only participants with no
missing data were included (n = 283). Likelihood ratio tests were used to calculate
p-values. Multivariable model adjusts for all listed variables. *Green Book risk
factors include current or intermittent drug use (history of IDU and current IDU),
being imprisoned, having liver disease and additionally being infected with HCV
on top of having liver disease. C/E Central and Eastern, CI Confidence Interval,
IDU injecting drug use, HCV Hepatitis C virus, OR odds ratio
Table 3 Extended multivariable analyses, separating the Green
Book risk factor exposure variable into four separate variables
Variable OR (95% CI)
Gender p = 0.005
Male (base)
Female 2.72 (1.35–5.48)
Age (linear) p = 0.12
19–29 (base)
per 10 year increase 1.22 (0.91–1.64)
Ethnicity p = 0.89
White C/E European 1.12 (0.53–2.37)
White Other (base)
Black African 1.32 (0.36–4.86)
Black Other 0.74 (0.31–1.78)
Mixed/Other 0.82 (0.30–2.28)
Birthplace p = 0.66
UK born (base)
Not UK born 0.83 (0.38–1.81)
Homelessness p = 0.62
Never (base)
History 0.72 (0.29–1.81)
Current 1.06 (0.45–2.50)
Excessive alcohol consumption p = 0.53
No (base)
Yes 0.72 (0.38–1.31)
History of smoking p = 0.17
No (base)
Yes 0.44 (0.13–1.45)
Drug Use p = 0.004
No drug use (base)
Non IDU (History or current) 0.55 (0.23–1.32)
History of IDU 0.17 (0.06–0.49)
Current IDU 0.23 (0.08–0.62)
Imprisonment/Arrested p = 0.03
Neither 1.79 (0.68–4.69)
Arrested but not imprisoned 2.59 (1.27–5.29)
Imprisoned (base)
History of liver disease p = 0.14
No (base)
Yes 1.97 (0.81–4.79)
HCV status p = 0.54
Negative (base)
Positive 1.47 (0.67–3.24)
Model presents a complete case analysis where only participants with no
missing data were included (n = 283). Likelihood ratio tests were used to
calculate p-values. *Green Book risk factors include current or intermittent
drug use (history of IDU and current IDU), being imprisoned, having liver
disease and additionally being infected with HCV on top of having liver
disease. C/E – Central and Eastern; CI confidence interval, HCV Hepatitis C
virus, IDU injecting drug use, OR odds ratio; p = p-value
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with an incomplete vaccine course decreased as the num-
ber of Green Book risk factors increased, two fifths of in-
dividuals lacked full vaccine protection among individuals
with one factor and nearly a quarter among individuals
with two or more. The presence of only a single factor
should be sufficient to trigger implementation of the
Green Book guidelines. Regression analyses confirmed
these findings and also highlighted the association of IDU
with vaccine coverage. Additionally, we found that females
were more likely to have an incomplete vaccination status.
The main reasons for given for participants having an in-
complete vaccination status was that they had not been
offered vaccination, or they had not returned to complete
the schedule.
As well as detailed documentation of vaccine coverage in
this critical population group for viral elimination, this is
the first study, to our knowledge, to examine the relation-
ship between Green Book risk factors and self-declared
vaccine uptake. The level of uptake documented within
PWIDs in our study (31%) falls within the range reported
from previous studies in PWIDs (27–66%), [24–26] al-
though it is lower than the latest figures charted by PHE in
PWIDs in 2016 of 71% [27]. UK prisons have reported
varying levels of HBV vaccine uptake (22–70.2%), depend-
ing on the type and location [28–31]. There is a lack of evi-
dence of HBV vaccine uptake in the homeless, although a
recent cross-sectional survey of a London homeless popu-
lation has estimated the prevalence of past HBV infection
as 10.4% and identified the importance of maximising vac-
cination uptake in this group [9]. Similarly, our study in-
cluded a number of homeless people without the presence
of other risk factors, who are not targets for the
pre-exposure HBV immunisation programme per se.
Interestingly, we also see 22.1% of people reporting a
complete vaccination status in the presence of no Green
Book risk factors, potentially reflecting previous travel
history, and also the nature of the population eligible for
the overarching trial i.e. individuals thought to be at
higher risk of chronic hepatitis C.
In agreement with previous studies in prisons, this
study found females were less likely to have reported re-
ceiving three doses of HBV vaccine [29, 32]. This could
be explained by both systems-related and personal fac-
tors, including healthcare workers prioritising males, as
most UK hepatitis cases (70.4%) are reported in men [3].
Our study also documents the self-declared reasons of the
participants about their lack of, or incomplete, HBV vaccine
uptake. Critically, among the non-vaccinated, 80% declared
that they had not been offered the vaccine, suggesting a lack
of vaccine availability or staff knowledge of the participants
and their risk factors. Similar healthcare system factors have
been noted by nurses in a previous study [24].
The principle limitation is that the study relies on
self-declared vaccine uptake. Due to unavailable data,
sexual preferences (such as men who have sex with men
and condom-less sex) could not be tested for association
with HBV vaccine uptake. This study recruited a specific
population that was in contact with outreach services to
a trial of Peer Advocates to improve engagement with
healthcare services and thus will not be representative of
the entire UK hard-to-reach population. Our study
undertook a complete case analysis, thus excluding data
from 63 patients, of whom 35 had an unknown vaccin-
ation status. We note that the population with an un-
known status may be older, with a differing history of
drug use, and imprisonment/arrest, thus slightly limiting
the generalisability of our findings.
Encouragingly, our analyses demonstrate that having a
Green Book risk factor is associated with receipt of a full
course of HBV vaccination, however, two fifths of indi-
viduals with only one Green Book risk factor reported
an incomplete vaccine course and one fifth with two or
more factors. More therefore needs to be done to im-
prove coverage, particularly among groups with the risk
factors that do not already lead to greater engagement
with care e.g. individuals with chronic HCV or liver dis-
ease. This study has highlighted that females have an in-
creased likelihood of incomplete vaccination, which is of
particular note, given that women tend to engage better
with healthcare in the general population. There was
also a lack of convincing evidence of the impact HCV
status or liver disease are associated with vaccination
status. Together with our analysis, of the self-declared
reasons for an incomplete vaccination status, this sug-
gests that there is a need for strengthening awareness
Table 4 Questionnaires captured reasons for participants not
being vaccinated against HBV or not completing the schedule
Reason for no/incomplete vaccination Frequency Percentage (%)
No vaccination 85 100
Never been offered the vaccine 68 80
Already had Hepatitis B 8 9.4
Do not have enough time 3 3.5
Refused vaccination 2 2.4
Allergic to other vaccines/potentially
this vaccine
1 1.2
Dislike needles 1 1.2
Do not believe in vaccination 1 1.2
Worried about side-effects 1 1.2
Incomplete vaccination 22 100
Did not return 13 59.1
Do not have enough time 5 22.7
Infected with Hepatitis B virus
between doses
2 9.1
Side effects/allergy to first dose(s) 1 4.6
Awaiting third dose 1 4.6
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about vaccine eligibility among the relevant population
groups and healthcare workers. Further qualitative re-
search should be done to look into the barriers and en-
ablers for returning and to help improve policy and
practice. One suggestion would be incentives to help
with adherence to the multi-dose vaccine schedule [33].
Conclusions
Within this study of HBV vaccination uptake among
hard-to-reach population groups in London, UK, we
document approximately 50% coverage of the full vac-
cine course and- critically- surprisingly low coverage in
the presence of the risk factors that are national indica-
tors for vaccination. We note particular population
groups associated with poorer vaccine uptake and the
need for better engagement of these groups with vaccine
delivery systems.
Additional files
Additional file 1: Study Questionnaire. The study questionnaire captured
social and medical history, demographic factors, information about HBV
vaccination status and reasons for incomplete vaccination if applicable. It
was completed by individuals consenting to participate in a randomised
controlled trial of a peer intervention to promote engagement with
hepatitis C services. (DOCX 824 KB)
Additional file 2: Baseline characteristics of the 346 participants, with
column percentages. (DOCX 30 KB)
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